Albarel (rilmenidin) - a selective agonist of imidazol receptors. II. Pharmacological properties and experience of clinical use


Cite item

Full Text

About the authors

V N Khirmanov

References

  1. Ланг Г. Ф. Гипертоническая болезнь. Л.: Медгиз; 1950.
  2. Esler M., Lambert С., Jennings G. Incresed regional sympaphetic nervous activity in human hypertension: causes and consequensres. J. Hypertens. 1990; 8(suppl. 7): S53-S57.
  3. Goldstein D. S. Stress, catecholamines and cardiovascular disease. New York: Oxford University Press; 1995.
  4. Borchard U. The role on the sympathetic nervous system in cardiovascular disease. J. Clin. Basic Cardiol. 2001; 4(2): 175- 177.
  5. Reaven G. M. Banting lecture 1988: Role of insulin resistance in human disease. Diabetes 1988; 37(12): 1595-1607.
  6. Kaplan N. M. The deadly quartet. Upper body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch. Intern. Med. 1989; 149(7): 1514-1607.
  7. Bousquet P., Feldman J., Bloch R., Schwartz J. The nucleus reticularis lateralis: a region highly sensitive to clonidine. Eur. J. Pharmacol. 1981; 69(3): 389-392.
  8. Bousquet P., Feldman J, Schwarts J. Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines. J. Pharmacol. Exp. Ther. 1984; 230(1): 232-236.
  9. Bousquet P. I, receptors, cardiovascular function, and metabolism. Am. J. Hypertens. 2001; 14(11, pt 2): 317S-321S.
  10. Lachaud-Pettiti V., Podevin R. A., Chretien Y., Parini A. Imidazoline-guanidinium and alpha 2-adrenergic binding sites in basolateral membranes from human kidney. Eur. J. Pharmacol. 1991; 206(1): 23-31.
  11. Coupry I., Podevin R. A., Dausse J. P., Parini A. Evidence for imidazoline sites in basolateral membranes from rabbit kidney. Biochem. Biophys. Res. Commun. 1987; 147(10): 1055-1060.
  12. Smyth D. D., Penner S. B. Renal 1,-Imadazoline receptor-selective compounds mediate natriuresis in the rat. J. Cardiovasc. Pharmacol.
  13. Reid J. L. Update on rilmeniine: clinical benefits. Am. J. Hypertens. 2001; 14(11, pt 2): 322S-324S.
  14. Kline R. L., Van der Mark J., Cechetto D. F. Natrieuretic effect of rilmenidine in anestherized rats. Am. J. Cardiol. 1994; 74(snppl.): 20A-24A.
  15. Chan S. L. F., Brown С A., Scarpello K. E., Morgan N. G. Imidazoline sites involved in control of insulin secretion. Br. J. Pharmacol. 1994; 112(4): 1065-1070.
  16. Genissel P., Bromet N.. Fourtillan G. B. et al. Pharmacokinatics of rilmenidine in healthy subjects. Am. J. Cardiol. 1988; 61(7): 47D-53D.
  17. Ostermann G., Brisgand В., Schmitt J., Fillastre J. P. Efficacy and acceptability of rilmendine for mild-to-moderate systemic hypertension. Ibid, (suppl.): 76D-80D.
  18. Fiorentini C., Guillet C., Guazzi M. Etude multicentrique en double avengle comparant la rilmendine 1 mg et ['hydrochlorothiazide 25 mg chez 244 patients. Arch. Mai. Coeur 1989; 82(suppl.): 39-46.
  19. Pelemans W., Verhaeghe J., Creytens G. et al. Efficacy and safety of rilmenidine in elderly patients: comparison with Hydrochlorthiazide. Am. J. Cardiol. 1994: 74(3): 51A-57A.
  20. Datlocchio M., Gosse P., Fillastre J. P. et al. Rilmenidine, a new antihypertensive agent, in the first-line treatment of essential hypertension. A multicentre double-blind study versus atenolol. Presse Med. 1991; 20(27): 1265-1271.
  21. Sadowski Z., Szwed H., Kuch-Wocial A. et al. Regression of left ventricular hypertrophy in hypertensive patients after 1 year of threatment with rilmenidine: a double-blind, randomized, controlled (versus rifedipine) study. J. Hypertens. 1998; 16(3, suppl.): S55-S62.
  22. Dupuy D., Barduceau В., Mayandon M. Efficacy of rilmenidine? Selective 1, imidazoline receptor agent in hypertensive diabetics. Am. J. Hypertens. 1999; 12(4, pt 2): 220A.
  23. Scemama M., Fevrier В., Beucker I. et al. Lipid profile and anthypertensive efficacy in dyslipidemic hypertensive patients: comparison of rilmenidine with captopril. J. Cardiovasc. Pharmacol. 1995; 26(suppl. 2): S34-S39.
  24. Trimarco B. Contribution of 1,-selcctive agent in tye management of hypertensive patients with metabolic syndrome X. Am. J. Hypertens. 1999; 12(4, pt 2): 221A.
  25. Dolleiy С. Т., Wilson I. V., Prangell A. A. Rilmenidine in mildto-modereate essential hypertension. Curr. Ther. Res. 1990; 47(2): 194-221.
  26. Fillastre J. P., Letac В., Galinier F. et al. A multicenter doubleblind comparative study of rilmenidine and clonidine in 333 hypertensive patients. Am. J. Cardiol. 1998; 61(7): 81D-85D.
  27. Beau В., Mahieux F., Paraire M. et al. Efficacy and safety of rilmenidine for arterial hypertension. Ibid. 95D-102D.
  28. Swanz J.. Chapuy P., Chignon J. C. Antihypertensive efficacy and acceptability of hyperium (rilmenidine) in long-term treatment. Expert Report. 1986.
  29. Luccioni R. Efficacy and acceptability of rilmenidine in 18235 hypertensive patients over 1 year. Presse Med. 1995; 24(38): 1857-1864.
  30. Passeron J., Guillet С. Treatment with rilmendine 1 mg per day: time-lag to maximum response. A multicenter ambulatory study. Le groupe francais d'etude multicentrique d'hyperium. Ibid. 1992; 21(43): 2089-2093.
  31. Panfibv V., Morris A. D., Donnelly R. et al. The effects or rimenidine and atenolol onmental stress, dynamic exercise and autonomic function in mild-to-moderate hypertension. Br. J. Clin. Pharmacol. 1995; 40(6): 563-569.
  32. Galley P., Manciet G., Hessel J. L., Michel J. P. Antihypertensive efficacy and acceptability of rilmenidine in elderly hypcrtmsive patients. Am. J. Cardiol. 1988; 61(6): 86D-90D.
  33. Velasco M., Soltero L, Sukerman M. Double-blind, randomized study of the efficacy, tolerance, and rebound effects of the antihypertensive drug rilmenidine: comparative evaluation with clonidine. Curr. Ther. Res. 1993; 4(2): 202-207.
  34. Mpoy M., Vandeleene В., Ketelegers J. M., Lambert A. E. Treatment of systemic hypertension in insulin-treated diabetes mellitus with rilmenidine. Am. J. Cardiol. 1988; 61(7): 91D-94D.
  35. Lubetzki J. Etude chez I'hypertendu diabetique non insulinodependant de la rilmenidine (S3341). Essai realize chez 16 patients traits pendant trois mois aux posologies joumalieres de 1 et 2 mg. Expert study. 1986.
  36. Penicaud L., Berthault M. F., Mirim J. et al. Rilmenidine normalizes fructose-induced insulin resistance and hypertension in rats. J. Hypertens. 1998; 16(suppl.): S45-S49.
  37. Deluca N., Izzo R., Fontanel D. et al. Haemodynamic and metabolic syndrome X. A double-blind study versus amlodipine. Ibid. 2000; 17(10): 1515-1522.
  38. Reid J. L. Rilmenidine: a clinical overview. Am. J. Hypertens. 2000; 13(6, pt2): 106S-1US.
  39. Lenguel M., Borbas S., Zorandi A. Regression of left ventricular hypertrophy in mi Id-mo derate hypertension in one year of treatment with nifedipine. Eur. Heart J. 2000; 2 l(suppl-): 101.
  40. Lepran I., Papp J. G. Effect of moxonidine on arrhythmias induced by coronary artery occlusion and reperfusion. J. Cardiovasc. Pharmacol. 1994; 24(suppl. I): S9-S15.
  41. Mammoto Т., Kamibayashi Т., Hayashi V. et al. Antiarrhythmic action of rilmenidine on adrenalineinduced arrhythmia via central imidazoline receptors in halothaneanaesthetized dogs. Br. J. Pharmacol. 1996; 117(8): 1744-1748.
  42. Roegel J. C., Yannoulis N.. De Jong W. et al. Inhibition of centrally induced ventricular arrhythmias by rilmenidine and idazoxan in rabbits. Naunyn Schmiedebergs Arch. Pharmacol. 1996; 354(5): 598-605.
  43. Bauduceau В., Mayandon H., Dupuy O. Rilmenidine in the hypertensive type 2 diabetic: a controlled pilot study versus captopril. J. Cardiovasc. Risk 2000; 7(1): 57-61.
  44. Maiese К., Рек L., Berger S. В., Reis D. J. Reduction in focal cerebral ischemia by agents acting at imidazoline receptors. J. Cereb. Blood Flow 1992; 12(1): 53-63.
  45. Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Артериал. гипертензия 2001; 7(1): 4-16.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2003 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies